Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current state of prognostication and risk stratification in myelodysplastic syndromes.

Current opinion in hematology - 1 Mar 2015

Zeidan Amer M, Gore Steven D, Padron Eric, Komrokji Rami S

Abstract excerpt

PURPOSE OF REVIEW: Myelodysplastic syndromes (MDS) are characterized by significant biologic and clinical heterogeneity. Because of the wide outcome variability, accurate prognostication is vital to high-quality risk-adaptive care of MDS patients. In this review, we discuss the current state of prognostic schemes for MDS and overview efforts aimed at utilizing molecular aberrations for prognostication in clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosome Aberrations
Share to Comorbidity
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Prognosis

Source

Identifiers

PMID: 25575032
DOI: 10.1097/MOH.0000000000000110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current state of prognostication and risk stratification in myelodysplastic syndromes.PMID 25575032Read ↗

The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.Semantic proximity Read ↗

The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Prognostic models in myelodysplastic syndromes.Semantic proximity Read ↗

Clinical and genetic predictors of prognosis in myelodysplastic syndromesSemantic proximity Read ↗

Novel Prognostic Models for Myelodysplastic Syndromes.Semantic proximity Read ↗

Updates in Risk Stratification in Myelodysplastic Syndromes.Semantic proximity Read ↗

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Semantic proximity Read ↗

Improving Prognostic Modeling in Myelodysplastic Syndromes.Semantic proximity Read ↗

There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Semantic proximity Read ↗

When to use which molecular prognostic scoring system in the management of patients with MDS?Semantic proximity Read ↗

New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.Semantic proximity Read ↗

MDS prognostic scoring systems – past, present, and future.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.